Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma

Peripheral T cell lymphoma (PTCL) represents a group of heterogeneous hematological malignancies, which are notoriously challenging to treat and outcomes are typically poor. Over the past two decades, clinical prognostic indices for patient risk stratification have evolved, while several targeted ag...

Full description

Saved in:
Bibliographic Details
Published inJournal of hematology and oncology Vol. 17; no. 1; pp. 38 - 20
Main Authors Chang, Esther Wei Yin, Tan, Ya Hwee, Chan, Jason Yongsheng
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 01.06.2024
BioMed Central
BMC
Subjects
Age
AITL
Antimitotic agents
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Chemotherapy
Development and progression
Drug therapy, Combination
Epigenetic inheritance
Epigenetics
Humans
Immunomodulation
Immunotherapy
Immunotherapy - methods
Lymphocytes
Lymphocytes T
Lymphoma
Lymphoma, T-Cell, Peripheral - drug therapy
Lymphoma, T-Cell, Peripheral - therapy
Malignancy
Medical prognosis
Medical research
Medicine, Experimental
Molecular Targeted Therapy - methods
Neoplasm Recurrence, Local
Non-Hodgkin's lymphomas
Patients
Precision medicine
Precision Oncology
Prognosis
Review
Risk Assessment
T cells
T-cell lymphoma
Asia
Japan
Epigenetics
Precision Oncology
Prognosis
Immunotherapy
AITL
Online AccessGet full text

Cover

More Information
Summary:Peripheral T cell lymphoma (PTCL) represents a group of heterogeneous hematological malignancies, which are notoriously challenging to treat and outcomes are typically poor. Over the past two decades, clinical prognostic indices for patient risk stratification have evolved, while several targeted agents are now available to complement combination chemotherapy in the frontline setting or as a salvage strategy. With further understanding of the molecular pathobiology of PTCL, several innovative approaches incorporating immunomodulatory agents, epigenetic therapies, oncogenic kinase inhibitors and immunotherapeutics have come to the forefront. In this review, we provide a comprehensive overview of the progress in developing clinical prognostic indices for PTCL and describe the broad therapeutic landscape, emphasizing novel targetable pathways that have entered early phase clinical studies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-024-01560-7